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Background: Fetal growth restriction is among the most common and complex problems in modern obstetrics.
Symphysis-fundus (SF) height measurement is a non-invasive test that may help determine which women are at
risk. This study is a systematic review of the literature on the accuracy of SF height measurement for the prediction
of small-for-gestational-age (SGA) status at birth in unselected and low-risk pregnancies.
Methods: The Medline, Embase, Cinahl, SweMed, and Cochrane Library databases were searched with no limitation
on publication date (through September 2014), which returned 722 citations. Two reviewers then developed a
short list of 51 publications of possible relevance and assessed them using the following inclusion criteria: cohort
study of test accuracy performed in a routine prenatal care setting; SF height measurement for all participants;
classification of SGA, defined as birth weight (BW) < 10th, 5th, or 3rd percentile or ≥ one or two standard deviations
below the mean; study conducted in Northern, Western, or Central Europe; USA; Canada; Australia; or New Zealand;
and sufficient data for 2 × 2 table construction. Quality of the included studies was assessed in duplicate using
criteria suggested by the Cochrane Collaboration. Review Manager 5.3 software was used to analyze the data,
including plotting of summary receiver operating curve spaces.
Results: Eight studies were included in the final dataset and seven were included in summary analyses. The
sensitivity of SF height measurement for SGA (BW < 10th percentile) prediction ranged from 0.27 to 0.76 and
specificity ranged from 0.79 to 0.92. Positive and negative likelihood ratios ranged from 1.91 to 9.09 and from 0.29
to 0.83, respectively.
Conclusions: SF height can serve as a clinical indicator along with other clinical findings, information about medical
conditions, and previous obstetric history. However, SF height has high false-negative rates for SGA. Clinicians must
understand the limitations of this test.
The protocol has been registered in the international prospective register of systematic reviews, PROSPERO
(Registration No. CRD42014008928, http://www.crd.york.ac.uk/prospero/display_record.asp?ID=CRD42014008928).
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Screening for fetal growth restriction (FGR) is one of the
main purposes of antenatal care.
FGR is used to describe a fetus that did not reach its
genetic growth potential and is associated with increased
risks of morbidity and mortality, as well as adverse effects
in childhood and later life [1-4]. Because no unanimously
agreed-upon definition of FGR currently exists, small-for-
gestational-age (SGA) is often used as a proxy. SGA is de-
fined as weight below a specific percentile for gestational
age, usually the 10th percentile. Although not all SGA ne-
onates are pathologically growth restricted, detection of
this group aims to facilitate the identification of at-risk
pregnancies requiring further investigation due to poten-
tial FGR. Early identification and appropriate management
of FGR can reduce perinatal morbidity and mortality [5].
In Scandinavia, screening relies on routine measurement
of SF height, complemented by ultrasound measurement
of fetal size in women with pregnancy complications or
with a relevant history or clinical evidence of FGR [6-8].
SF height is a technique involving measurement of the
maternal abdomen from the symphysis pubis to the uter-
ine fundus with a tape measure. The measurement is plot-
ted on a curve and compared with the distribution of the
reference population [9,10]. If the recorded measurement
is below acceptable limits according to the reference
curves, further investigations of fetal growth and well-
being are to be performed, including ultrasound estima-
tions, uteroplacental and fetoplacental flow evaluations by
Doppler, as well as cardiotocography.
Despite the routine use of SF height to predict SGA at
birth, evidence for this method remains unclear. To date
there is insufficient evidence from high quality trials to
fully evaluate the effect of routine use of SF height during
prenatal care on pregnancy outcomes [11]. Several studies
have examined the accuracy of SF height in predicting
SGA status at birth, but inconsistency in the results has
been observed [12]. Most SF height research has been
conducted in hospital-based settings and has investigated
the relationship between SF height and SGA status in high
risk populations [13-15]. Because of a different prevalence
(pre-test probability) of SGA, results from hospital-based
studies cannot be extrapolated to primary care settings.
Objectives
In this systematic review we aim to assess the sensitivity
and specificity of SF height for the prediction of SGA
status at birth in unselected and low-risk pregnancies.
Methods
Criteria for considering studies for this review
Studies were selected for inclusion in the review accord-
ing to the population, index test, target condition, refer-
ence standard, outcome measure, and study design.Population
Studies examining singleton pregnancies in unselected or
low-risk populations, conducted in comparable health care
systems to Scandinavia (Northern, Western and Central
Europe, USA, Canada, Australia, and New Zealand).
Index test





Diagnosis of FGR or SGA, defined as birth weight
(BW) < 10th, 5th, or 3rd percentile, or ≥ one or two
standard deviations (SDs) below the mean (performed
postnatally).
Outcome measures
Data required to populate 2 × 2 contingency tables.
Study design
Diagnostic cohort studies.
Search methods for identification of studies
Electronic databases (PubMed, Medline, Embase, CINAHL,
Cochrane Library, and SweMEd) were searched to identify
eligible diagnostic studies from the earliest year pos-
sible through September 2014. The search strategy was
developed for PubMed and modified for use in other
databases (see Additional file 1). The reference lists of
all included publications and relevant systematic re-
views were checked and forward citation searches were
performed.
Electronic searches
The search strategy involved combinations of SF-related
terms appearing in subject headings and as keywords.
Our Medline search query was (fund* adj height*) OR
(symph* adj fund*) OR (uter* adj height*) OR (symph*
adj height*) OR (gravidogram*) OR (uterus fundus
height*) OR (uter* fund* height*). We conducted our
search and reported our findings according to the Meta-
Analysis of Observational Studies in Epidemiology and
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses statements [16-18].
Data collection and analysis
Study selection
A list of articles meeting the inclusion criteria based on
abstracts was compiled. The full texts of these studies
and those of uncertain relevance were retrieved. Two re-
viewers (ASDP and JW) independently evaluated the
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crepancy discussed with a third reviewer until a final set
of relevant studies was agreed upon.
Data extraction and management
The following data were extracted from all selected stud-
ies: general information (first author, publication year,
country of investigation), population (health care setting,
number of participants, level of risk), study design (de-
sign, data collection), characteristics of SF height test
(SF height curve, cut-off points), reference standard
(SGA definition) and results (data required for the con-
struction of 2 × 2 contingency tables). Data were entered
into a database using Review Manager 5.3 software.
Assessment of methodological quality
The quality of each included study was assessed by two re-
view authors (ASDP, JW) using the QUality Assessment of
Diagnostic Accuracy Studies (QUADAS-2) checklist
[19,20]. The QUADAS-2 checklist asks signaling questions
in four risks of bias domains relating to patient selection,
index test, reference standard, and flow and timing. Each
domain is assessed in terms of risk of bias, and the first
three domains are also assessed in terms of applicability.
The review authors classified each item as “yes” (adequately
addressed), “no” (inadequately addressed), or “unclear” (in-
adequate detail presented to allow a judgment to be made).
The QUADAS-2 tool is shown in Additional file 2.
Statistical analysis and data synthesis
Data on sensitivity, specificity, and true-positive, false-
positive, true-negative, and false-negative results were taken
directly from the source papers or, if necessary, calculated
from the data provided. Positive likelihood ratios (PLRs),
negative likelihood ratios (NLRs), diagnostic odds ratios
(DORs), and 95% confidence intervals (CIs) were calculated.
An LR describes how many times more likely it is that a
person with the target condition will receive a particular
test result than will a person without it. Categorization of
LRs was adopted from Deeks et al. [21] where PLRs > 10
or NLRs < 0.1 are considered to provide convincing diag-
nostic evidence. The DOR is commonly used as an overall
indicator of diagnostic performance and calculated as the
odds of a positive test result among those with the target
condition, divided by the odds of a positive test result
among those without the condition. As a general rule, a
DORs > 100 indicates high accuracy, values of 25–100 in-
dicate moderate accuracy, and those < 25 indicates that
the test is not useful [21].
The data were displayed graphically on forest and
summary receiver operating characteristic (SROC) plots
[22]. The SROC curve was fitted using the hierarchical
bivariate random-effects method [23]. For studies thatused more than one SF threshold, the analysis was based
on the cut-off point of “one value < 10th percentile”.
Investigation of heterogeneity
Both clinical and statistical heterogeneity were evaluated.
Assessment of clinical heterogeneity involved comparison
of SF reference curves, cut-off criteria used to identify ab-
normal results, and SGA definitions. Assessment of statis-
tical heterogeneity involved visual inspection of forest
plots and calculation of the inconsistency index (I2), which
describes the percentage of total variation across studies
that is due to heterogeneity, rather than chance [24].
Results
Initial database searches retrieved 722 citations of which 525
citations remained after duplicates were removed (Figure 1).
Screening of the titles and abstracts identified 51 potentially
relevant articles that were retrieved in full text format. For-
ward and backward citation tracking did not result in the
identification of additional relevant articles. Eight articles
were included in final analyses. Additional file 3 lists the rea-
sons for excluding 43 articles on the basis of study popula-
tion, design or outcome measures.
Included studies
Characteristics of included studies [25-32] are presented
in Table 1. All studies were published before 1991. Most
studies used locally derived SF curves. Different cut-off
criteria were used to identify abnormal results, including
one value < 10th percentile; two consecutive or three iso-
lated values < 10th percentile; one value > 2 cm below
the mean; one value > 2 cm below the mean or three
static or falling values; and one value > two SDs below
the mean. Definitions of SGA included BW < 10th per-
centile, < 5th percentile, and ≥ two SDs below the mean,
according to local standards.
Methodological quality of included studies
The QUADAS-2 ratings of risk of bias and study applic-
ability are shown in Table 2. Based on the inclusion cri-
teria, no included study had a case–control design. All
studies avoided inappropriate exclusions. Six of the eight
studies used consecutive or random recruitment of par-
ticipants. The two remaining studies [30,32] did not re-
port such information and were considered to be at
unclear risk of patient selection bias. Most studies had a
low risk of bias due to patient flow and timing; seven of
eight studies involved the analysis of all recruited partici-
pants and one analysis included 78% of recruited partici-
pants [32]. Studies included in this review had a low risk of
bias for the conduct of the reference standard. All studies
used pre-specified index test thresholds. No study reported
blinding to test results, but BW is objective and should not
result in bias. Regarding the applicability of studies to the
Table 1 Characteristics of included studies
Study Year Country n SF curve Cut-off defining abnormal test Definition of SGA
Calvert
et al. [25]
1982 Great Britain 381 local One value < 10th percentile, two consecutive values or
three isolated values < 10th percentile, one value≥ 3 cm
below mean or three consecutive static or falling values




1988 Sweden 3038 Westin One or more values≥ 3 cm below mean or falling or
static values
≥ two SDs below mean
Jensen
et al. [27]
1991 Norway 831 Westin One or more values≥ 3 cm below mean < 10th percentile
Pearce
et al. [28]
1987 Great Britain 699 local One value < 10th percentile < 10th percentile
Persson
et al. [29]
1986 Sweden 2919 local One value > two SDs below mean < 10th percentile
Rogers
et al. [30]
1985 Great Britain 250 local One or more values≥ 3 cm below mean or three









1989 Great Britain 1139 Calvert One or more values < 10th percentile after 26 weeks
or falling or static values
< 10th percentile
n, number of patients; SD, standard deviation; SF, symphysis-fundus; SGA, small-for-gestational-age.
Figure 1 Flow diagram. PRISMA flow diagram of studies through the review.
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Table 2 Risk of bias and applicability concerns summary

















low low low low low low low
Cnattingius
et al. [26]
low low low low low low low
Jensen
et al. [27]
low low low low low low low
Pearce
et al. [28]
low low low low low low low
Persson
et al. [29]
low low low low low low low
Rogers
et al. [30]
unclear low low low low low low
Rosenberg
et al. [31]
low low low low low low low
Stuart
et al. [32]
unclear low low unclear low low low
Risk of bias and applicability concerns summary based on the QUADAS-2 checklist.
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test, reference standard or patient selection.
Statistical analysis
Tables 3, 4, 5 display core information collected from all
included studies according to the SGA definition used by
the study authors.Table 3 Accuracy of symphysis-fundus height in predicting sma
with 95% confidence intervals
SF cut-off n Sensitivity Specificity
One value < 10th percentile
Calvert et al. [25] 381 0.64 (0.49-0.78) 0.79 (0.74-0.83
Pearce et al. [28] 699 0.76 (0.66-0.84) 0.79 (0.75-0.82
Stuart et al. [32] 1139 0.51 (0.40-0.61) 0.88 (0.86-0.90
Two consecutive values or
three isolated values < 10th
percentile
Calvert et al. [25] 381 0.36 (0.22-0.51) 0.94 (0.91-0.96
Rosenberg et al. [31] 761 0.56 (0.41-0.70) 0.85 (0.82-0.87
One value ≥ 3 cm below
mean
Jensen et al. [27] 831 0.41 (0.31-0.51) 0.87 (0.85-0.90
One value ≥ 3 cm below mean
or three consecutive static or
falling values
Calvert et al. [25] 381 0.76 (0.60-0.87) 0.60 (0.55-0.66
Rogers et al. [30] 250 0.73 (0.52-0.88) 0.92 (0.88-0.95
One value > two SDs below mean
Persson et al. [29] 2919 0.27 (0.21-0.32) 0.88 (0.87-0.89
DOR, diagnostic odds ratio; LR, likelihood ratio; n, number of patients; SD, standard
Accuracy of symphysis-fundus height in predicting small-for-gestational-age statusAccuracy of SF height for the prediction of SGA defined as
BW < 10th percentile
Seven studies assessed the accuracy of SF height for the
prediction of SGA defined as BW< 10th percentile. Sensi-
tivities ranged from 0.27 to 0.76 and specificities ranged
from 0.79 to 0.92. All studies produced DORs exceeding 1
and CIs that did not include 1, implying that the positivell-for-gestational-age status (birth weight < 10th percentile)
Positive LR Negative LR DOR
) 3.05 (2.26-4.12) 0.45 (0.30-0.67) 6.76 (3.48-13.14)
) 3.61 (2.99-4.37) 0.30 (0.21-0.43) 11.89 (7.22-19.58)
) 4.19 (3.22-5.46) 0.56 (0.45-0.70) 7.45 (4.71-11.80)
) 5.69 (3.21-10.07) 0.69 (0.55-0.86) 8.28 (3.90-17.58)
) 3.65 (2.70-4.92) 0.52 (0.38-0.71) 7.01 (3.87-12.71)
) 3.25 (2.38-4.42) 0.68 (0.57-0.80) 4.78 (3.01-7.59)
) 1.91 (1.54-2.36) 0.40 (0.24-0.68) 4.72 (2.31-9.64)
) 9.09 (5.51-15.00) 0.29 (0.16-0.55) 31.06 (11.53-83.72)
) 2.22 (1.77-2.78) 0.83 (0.77-0.90) 2.66 (1.97-3.58)
deviation; SF, symphysis-fundus.
(birth weight < 10th percentile) with 95% confidence intervals.
Table 4 Accuracy of symphysis-fundus height in predicting small-for-gestational-age status (birth weight < 5th percentile)
with 95% confidence intervals
SF cut-off n Sensitivity Specificity Positive LR Negative LR DOR
One value < 10th percentile
Calvert et al. [25] 381 0.60 (0.39-0.79) 0.76 (0.71-0.80) 2.51 (1.74-3.64) 0.53 (0.32-0.85) 4.78 (2.07-11.04)
Two consecutive values
or three isolated values < 10th
percentile
Calvert et al. [25] 381 0.36 (0.18-0.57) 0.92 (0.89-0.95) 4.58 (2.43-8.61) 0.69 (0.52-0.93) 6.59 (2.67-16.26)
One value ≥ 3 cm below mean
or three consecutive static or
falling values
Calvert et al. [25] 381 0.72 (0.51-0.88) 0.58 (0.53-0.63) 1.72 (1.31-2.26) 0.48 (0.26-0.91) 3.57 (1.46-8.77)
DOR, diagnostic odds ratio; LR, likelihood ratio; n, number of patients; SD, standard deviation; SF, symphysis-fundus.
Accuracy of symphysis-fundus height in predicting small-for-gestational-age status (birth weight < 5th percentile) with 95% confidence intervals.
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alone. PLRs exceeded 1 in all studies, indicating that ab-
normal SF height values were associated with SGA status
at birth. However all PLRs were <10, the threshold gener-
ally accepted for a useful test. The same seven studies re-
ported NLRs < 1, indicating that normal SF height values
were correctly associated with the absence of SGA. How-
ever, no study met the accepted criterion of NLR < 0.1 in
this group of women. The SROC curve (Figure 2) con-
structed using data from these studies lies to the left of the
diagonal, signifying that the SF height test has value. The
I2 value was typically high (98%). Given the small number
of included studies (and thus low statistical power), sub-
group analyses and covariate hierarchical modeling to in-
vestigate heterogeneity were not performed.
Accuracy of SF height for the prediction of SGA defined as
BW <5th percentile
One study assessed the accuracy of SF height for the
prediction of SGA defined as BW < 5th percentile. This
study used several cut-off points, with stricter criteria
yielding lower sensitivity and higher specificity values.
NLRs and PLRs did not meet the accepted criteria for
classification of SF height measurement as a useful test.
Accuracy of SF height for the prediction of SGA defined as
BW ≥ 2 SDs below the mean
One study assessed the outcome of SGA defined as
BW ≥ 2 SDs below the mean. For a less strict SF cut-offTable 5 Accuracy of symphysis-fundus height in predicting se
standard deviations below the mean) with 95% confidence in
SF cut-off n Sensitivity Specificity
One value ≥ 3 cm below mean or falling or static values
Cnattingius et al. [26] 3038 0.59 (0.39-0.78) 0.97 (0.96-0.98)
DOR, diagnostic odds ratio; LR, likelihood ratio; n, number of patients; SD, standard
Accuracy of symphysis-fundus height in predicting severe small-for-gestational-age
confidence intervals.point (one value > 2 cm below mean or falling or static
values), the authors reported low sensitivity (59%) and
high specificity (97%). The PLR exceeded 10, but the
NLR did not meet the required criterion of <0.1.
Discussion
SF height measurement seems to have some significance
for the prediction of SGA defined as BW< 10th percentile.
All studies reported DORs > 1. The SROC curve (Figure 2)
lies to the left of the diagonal, signifying that the SF height
test has value. Adequate levels of sensitivity appear to be
achieved at the expense of lower specificity, with higher
numbers of false-positive SF results. The study of Rogers
et al. [30] positioned at the upper left of the SROC curve
produced the most significant results supporting the use
of SF height. Its false negative rate of only seven is likely
to be due to the small size of the study. In contrast, the
study of Persson et al. [29] is the largest study and has the
narrowest CI. Its sensitivity and specificity lies along the
SROC line, adding weight to our findings.
For the prediction of SGA defined as BW < 5th per-
centile and BW ≥ 2 SDs below the mean, no summary
measure could be performed due to the insufficient
number of studies assessing these outcomes. Further as-
sessment of the predictive value of SF in prediction of
SGA defined as BW < 5th percentile and BW ≥ 2 SDs
below the mean is required.
The diagnostic accuracy of SF height in other popula-
tions of pregnant women has recently been reviewed.vere small-for-gestational-age status (birth weight ≥ two
tervals
Positive LR Negative LR DOR
19.83 (13.65-28.79) 0.42 (0.27-0.66) 47.21 (21.30-104.62)
deviation; SF, symphysis-fundus.
status (birth weight ≥ two standard deviations below the mean) with 95%
Figure 2 Summary receiving operating characteristic plot. Summary receiving operating characteristic plot of symphysis-fundus height measurement
for the prediction of small-for-gestational-age status (birth weight < 10th percentile).
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mainly in developing countries. However, this review in-
cluded studies across a wide range of ethnic groups,
clinical settings and disease spectrums. Despite such a
diverse case mix, the study did not assess its effect on
the pooled estimates, thus making it difficult to interpret
its finding in a low-risk setting. In view of these limita-
tions, we applied more strict inclusion criteria in our
study, focusing mainly on a more homogenous and rele-
vant population.Strengths and weaknesses of the review
The majority of studies available in this systematic re-
view were conducted in the 1980s. Given the limited
amount of data available for the accuracy of SF height
measurement, we did not discard studies based solely on
year of publication. All included studies had low concern
regarding applicability, implying that evidence is relevant
to current practice. The focus on nations with compar-
able health systems means that the findings may not berelevant to different and less well-resourced national
health systems.
Many parameters involving the performance of SF
height measurement, such as technique, frequency of
measurement, and performer’s experience, potentially
affect test accuracy. Unfortunately, we did not have de-
tailed information about the test conditions, limiting our
ability to explore the effects of potential differences in
methods. As no universal SGA definition has been
established, the studies included in this review may also
have been biased by the choice of reference test. Our in-
clusion criteria required postnatal confirmation of SGA
classification. All studies fulfilled this requirement, but
most did not provide information about how gestational
age was determined or which BW reference were used
to classify SGA status postnatally.
This review focused on the role of SF height in detect-
ing SGA as a proxy for FGR. However, FGR can exist
without SGA. The role of SF height in this setting re-
mains undefined because all SF height studies in this re-
view used SGA as an outcome. Customized SF charts
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said to be better predictors of FGR [34]. Furthermore,
this review did not address the issue of effect, for which
additional studies would be needed to assess the role of
SF height.
Ultimately, the lack of large cohort studies conducted
in routine prenatal care setting that were suitable for our
analysis was the main limitation of this review.Applicability of findings to clinical practice and policy
SF height can be the first parameter raising suspicion of
FGR. We have previously discussed the limitations of
the study populations. However, our results can be ap-
plied to low-risk and unselected pregnancies in routine
prenatal care setting, which is useful for general practi-
tioners and midwifes to assure the identification of preg-
nancies at risk of SGA.
We found that the SF height test had a sensitivity ran-
ging from 0.27 to 0.76, which means it potentially fails
to identify over 70% of pregnancies affected by SGA.
This is important to consider in counselling of pregnant
women. However, in clinical practice the SF height test
is not carried out in isolation and the combination of
other clinical findings, medical conditions and previous
obstetric history, together will contribute to estimating
the likelihood of being at risk for SGA.
Our results show that the SF height test has a high de-
gree of specificity (≥80% in all studies), indicating that
few pregnancies not characterized by SGA are referred
for ultrasound examination in practice. However, in this
case over-referral or the misidentification of pregnancies
as at risk is of less concern than the failure to identify
pregnancies at risk.
Primary screening should emphasize the importance
of sensitivity over specificity to identify almost all at-risk
participants. No test is perfect and there will always be
problems with incorrect results, e.g., anxiety and un-
necessary intervention due to a false-positive result or a
false sense of security caused by a false-negative result.
A positive SF screening result can usually be confirmed
or refuted with further evaluation of fetal growth and
well-being by a specialist.Conclusion
Implications for practice
SF height can play a role in clinical practice. It is a non-
invasive, simple, and inexpensive method. However, it
has low sensitivity. Other techniques that could improve
upon this limitation (e.g., routine ultrasound in the third
trimester) have not been implemented in the routine
prenatal care setting [35]. We recommend the continued
use of SF height measurement in clinical practice as one
of several indicators for referral to an obstetric care unit.However, clinicians must understand the limitations of
the test.
Implications for research
Further studies including larger numbers of patients and
better standardized reporting criteria are desirable. The
accuracy of adjusted over unadjusted SF curves needs to
be evaluated.
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